Fig. 4From: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trialsMean change in central macular thickness (μm) from baseline comparing bevacizumab with ranibizumab at 1 and 2 years. IV, inverse variance; SD, standard deviationBack to article page